Table 1.
Number and percentage of psoriatic patients treated with a biological agent in Italy. Period: 22 February 2020–22 April 2020
| ADA | ETA | INF | UST | SEC | IXE | BRO | GUS | TIL | RIS | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total patients | 3045 | 1645 | 343 | 2638 | 2417 | 1586 | 297 | 628 | 16 | 192 | 12 807 |
| Mean % of treated patients for each biological drugs | 23.8% | 12.8% | 2.7% | 20.6% | 18.9% | 12.4% | 2.3% | 4.9% | 0.1% | 1.5 | 100% |
| Patients stopping therapy autonomously † | 90 (3.0%) | 49 (3.0%) | 19 (5.5%) | 72 (2.7%) | 49 (2.0%) | 32 (2.0%) | 5 (1.7%) | 9 (1.4%) | 0 | 3 (1.6%) | 328 (2.6%) |
| Patients stopping therapy after consulting with the physician † | 85 (2.8%) | 30 (1.8%) | 10 (2.9%) | 21 (0.8%) | 36 (1.5%) | 8 (0.5%) | 5 (1.7%) | 13 (2.1%) | 0 | 4 (2.1%) | 233 (1.8%) |
| Patients’ LTIs of therapy autonomously † | 47 (1.5%) | 61 (3.7%) | 5 (1.5%) | 28 (1.1%) | 27 (1.1%) | 9 (0.6%) | 2 (0.7%) | 4 (0.6%) | 0 | 2 (1.0%) | 185 (1.4%) |
| Patients’ LTIs of therapy after consulting with the physician † | 25 (0.8%) | 6 (0.4%) | 11 (3.2%) | 26 (1.0%) | 10 (0.4%) | 26 (1.6%) | 1 (0.3%) | 5 (0.8%) | 0 | 4 (2.1%) | 114 (0.9%) |
ADA, adalimumab; BRO, brodalumab; ETA, etanercept; GUS, gusesslkumab; INF, infliximab; IXE, ixekizumab; LTIs, lengthening of time intervals; RIS, risankizumab; SEC, secukinumab; TIL, tildrakizumab; UST, ustekinumab.
†
Percentages are calculated on the total number of patients.